Astra’s Tagrisso Gets U.K. Backing After Price Agreement

Updated on
  • 300 lung cancer patients in England, Wales will be eligible
  • NICE issued draft recommendation against Merck’s Keytruda

AstraZeneca Plc, the U.K.’s second-largest drugmaker, won the endorsement of the country’s health-cost regulator for use of its Tagrisso medicine, while a competing lung-cancer drug from Merck & Co. was rejected as not being cost-effective.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.